Bicocca Open Archive

Logo unimib boa
MOLOGNI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.816
AS - Asia 7.254
EU - Europa 6.409
SA - Sud America 1.176
AF - Africa 156
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 16
Totale 26.844
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.522
SG - Singapore 2.713
CN - Cina 1.706
IT - Italia 1.670
VN - Vietnam 1.100
DE - Germania 985
RU - Federazione Russa 979
BR - Brasile 941
HK - Hong Kong 908
IE - Irlanda 641
SE - Svezia 622
GB - Regno Unito 343
UA - Ucraina 302
CA - Canada 200
FR - Francia 190
IN - India 175
FI - Finlandia 165
PL - Polonia 142
KR - Corea 119
ID - Indonesia 108
AR - Argentina 104
TR - Turchia 84
JP - Giappone 79
NL - Olanda 75
BE - Belgio 68
BD - Bangladesh 65
MX - Messico 65
ZA - Sudafrica 64
ES - Italia 59
AT - Austria 42
DK - Danimarca 36
IQ - Iraq 35
EC - Ecuador 34
PK - Pakistan 27
LT - Lituania 25
MA - Marocco 24
CO - Colombia 21
VE - Venezuela 20
PE - Perù 19
KE - Kenya 18
SA - Arabia Saudita 18
IR - Iran 16
PY - Paraguay 16
TN - Tunisia 16
CL - Cile 14
EU - Europa 14
UZ - Uzbekistan 13
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
NP - Nepal 11
AU - Australia 10
JO - Giordania 10
AZ - Azerbaigian 9
EG - Egitto 9
ET - Etiopia 9
CZ - Repubblica Ceca 8
KZ - Kazakistan 7
MY - Malesia 7
RO - Romania 6
NO - Norvegia 5
NZ - Nuova Zelanda 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
BG - Bulgaria 4
CR - Costa Rica 4
GR - Grecia 4
IL - Israele 4
MK - Macedonia 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
AL - Albania 3
AM - Armenia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HN - Honduras 3
MD - Moldavia 3
MU - Mauritius 3
NI - Nicaragua 3
PA - Panama 3
PS - Palestinian Territory 3
TH - Thailandia 3
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
DZ - Algeria 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
OM - Oman 2
PR - Porto Rico 2
PT - Portogallo 2
RS - Serbia 2
SC - Seychelles 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
Totale 26.825
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.939
Singapore 1.469
Ashburn 1.210
Hong Kong 903
Woodbridge 726
Fairfield 689
Milan 677
Frankfurt am Main 631
Dublin 630
Chandler 602
Wilmington 445
Houston 441
Dallas 367
Ho Chi Minh City 359
New York 352
Beijing 279
Hanoi 271
Jacksonville 268
Seattle 265
Hefei 262
Los Angeles 256
Cambridge 247
Dearborn 247
Santa Clara 237
Princeton 172
San Jose 164
Shanghai 130
Nanjing 124
The Dalles 117
Seoul 106
São Paulo 103
Munich 101
Buffalo 97
Moscow 92
Jakarta 88
Chicago 84
Altamura 83
Lawrence 79
Lodz 70
Tokyo 66
Helsinki 64
Warsaw 62
Brussels 59
San Diego 49
Da Nang 47
Guangzhou 47
Nuremberg 45
Lachine 44
London 44
Council Bluffs 43
Johannesburg 43
Toronto 43
Boardman 42
Rio de Janeiro 42
Kent 41
Montreal 40
Poplar 40
Turku 40
Fremont 39
Haiphong 38
Rome 38
Denver 37
Orem 37
Chennai 36
Lissone 36
Shenyang 36
Brooklyn 35
Phoenix 35
Atlanta 33
Nanchang 33
Stockholm 33
Andover 31
Desio 31
Ottawa 29
Romola 29
Ankara 27
Boston 27
Göttingen 27
Jinan 27
Salt Lake City 27
Changsha 26
Hải Dương 25
Tianjin 25
Ha Long 24
Monza 24
Biên Hòa 22
Jiaxing 22
Mexico City 22
San Francisco 22
Amsterdam 21
Carate Brianza 21
Falls Church 21
Hebei 20
Kunming 20
Pune 20
Sesto San Giovanni 20
Curitiba 19
Manchester 19
Mountain View 19
Norwalk 19
Totale 17.435
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 445
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 405
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 404
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 401
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 377
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 365
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 359
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 358
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 347
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 345
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 330
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 326
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 322
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 321
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 315
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 310
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 305
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 302
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 292
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 289
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 289
Inhibition of RET tyrosine kinase by SU5416 287
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 285
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 281
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 279
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 278
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 278
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 277
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 277
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 276
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 275
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 274
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 273
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 272
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 271
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 266
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 264
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 262
Dual kinase targeting in leukemia 259
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 258
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 258
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 256
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 253
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 251
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 246
Efficacy of a cancer vaccine against ALK-rearranged lung tumors 244
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 244
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 242
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 242
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 237
We shall overcome (drug resistance) some day 237
Expression, purification, and inhibition of human RET tyrosine kinase 236
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 227
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 224
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 224
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 223
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 223
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 220
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 218
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 215
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 212
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 209
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 207
Novel targeted therapeutics for MEN2 205
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 203
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 201
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 196
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 195
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 195
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 194
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 193
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition 192
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 191
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells 189
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting 189
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 188
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 186
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 186
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 184
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 184
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 183
Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity 181
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer 181
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- thienyl)nicotinonitrile scaffold 181
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 181
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 180
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 178
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice 175
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 173
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 173
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 172
Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl 170
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 169
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 168
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 165
Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR 163
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo 163
Anaplastic Lymphoma kinase assay, reagents and composition thereof 160
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 154
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 153
Totale 24.441
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.402
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.402
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.109 0 0 0 0 0 0 179 214 187 204 151 174
2021/20221.316 112 154 136 70 54 102 80 72 62 119 147 208
2022/20232.642 289 734 209 237 176 353 28 138 180 134 85 79
2023/20242.204 113 87 98 113 255 562 400 68 177 57 55 219
2024/20255.508 275 476 319 278 440 200 369 193 548 880 492 1.038
2025/20268.607 1.935 1.030 1.206 1.673 1.644 753 366 0 0 0 0 0
Totale 27.567